Innoviva (INVA) Tops Q3 EPS by 71c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 1, 2023 4:15 PM EDTReceived GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023
Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter
Announced positive topline Phase 3 zoliflodacin data for treatment of gonorrhea in November 2023
Repurchased $11.0 million of common stock
BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (Innoviva or the Company), a diversified holding company with a portfolio of royalties and other healthcare assets,... More
